Literature DB >> 24218540

Chemopreventive effects of an HDAC2-selective inhibitor on rat colon carcinogenesis and APCmin/+ mouse intestinal tumorigenesis.

Durgadevi Ravillah1, Altaf Mohammed, Li Qian, Misty Brewer, Yuting Zhang, Laura Biddick, Vernon E Steele, Chinthalapally V Rao.   

Abstract

Epigenetic modulators, particularly histone deacetylases (HDACs), are valid targets for cancer prevention and therapy. Recent studies report that HDAC2 overexpression is associated with colon tumor progression and is a potential target for colon cancer prevention. This study tested chemopreventive and dose-response effects of Ohio State University HDAC42 (OSU-HDAC42), a selective HDAC2 inhibitor, using a rat colon carcinogenesis model to assess aberrant crypt foci inhibition and a familial adenomatous polyposis model to assess intestinal tumor inhibition. Colonic aberrant crypt foci were induced by azoxymethane (AOM) (15 mg/kg body weight, once-weekly subcutaneous injections at 8 and 9 weeks age). One week after AOM treatment, groups of rats were fed an AIN-76A diet containing 0, 75, 150, and 300 ppm OSU-HDAC42 for 8 weeks, and colonic aberrant crypt foci were evaluated. To assess the inhibitory effect of OSU-HDAC42 on small-intestinal polyps and colon tumor growth, 6-week-old male C57Bl/6J-APC(min/+)mice were fed an AIN-76A diet containing 150 ppm OSU-HADC42 or 300 ppm pan-HDAC inhibitor suberoylanilide hydroxyamic acid (SAHA) for 80 days. Our results demonstrate that dietary OSU-HDAC42 produced dose-dependent inhibition of AOM-induced colonic aberrant crypt foci formation (13-50%; P < 0.01 to < 0.0001) and reduced multiple crypts with ≥ 4 crypts per focus (25-57%; P < 0.01 to < 0.0001) in F344 rats. Our findings show that 150 ppm OSU-HDAC42 significantly inhibited small-intestinal polyps (>46%; P < 0.001), with polyp size measuring >1 mm (P < 0.001), and colon tumors (>26%) in APC(min/+)mice, whereas 300 ppm SAHA showed nonsignificant inhibition. Mice fed 150 ppm OSU-HDAC42 had significantly decreased HDAC2, proliferating cell nuclear antigen, B cell lymphoma 2, cyclin-dependent kinase 2, and cell division cycle homolog 25C expression levels and increased p53 expression levels. These observations demonstrate the chemopreventive efficacy of OSU-HDAC42 against chemically induced and polyposis models of intestinal tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24218540      PMCID: PMC3868878          DOI: 10.1124/jpet.113.208645

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  45 in total

1.  The language of covalent histone modifications.

Authors:  B D Strahl; C D Allis
Journal:  Nature       Date:  2000-01-06       Impact factor: 49.962

Review 2.  Apoptosis-based therapies.

Authors:  John C Reed
Journal:  Nat Rev Drug Discov       Date:  2002-02       Impact factor: 84.694

Review 3.  Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer.

Authors:  Saverio Minucci; Pier Giuseppe Pelicci
Journal:  Nat Rev Cancer       Date:  2006-01       Impact factor: 60.716

4.  Histone H4-K16 acetylation controls chromatin structure and protein interactions.

Authors:  Michael Shogren-Knaak; Haruhiko Ishii; Jian-Min Sun; Michael J Pazin; James R Davie; Craig L Peterson
Journal:  Science       Date:  2006-02-10       Impact factor: 47.728

Review 5.  Serrated pathway colorectal cancer in the population: genetic consideration.

Authors:  Joanne Young; Mark Jenkins; Susan Parry; Bruce Young; Derek Nancarrow; Dallas English; Graham Giles; Jeremy Jass
Journal:  Gut       Date:  2007-06-12       Impact factor: 23.059

Review 6.  Lessons from hereditary colorectal cancer.

Authors:  K W Kinzler; B Vogelstein
Journal:  Cell       Date:  1996-10-18       Impact factor: 41.582

7.  PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs.

Authors:  T C He; T A Chan; B Vogelstein; K W Kinzler
Journal:  Cell       Date:  1999-10-29       Impact factor: 41.582

8.  Histone deacetylase 2 modulates p53 transcriptional activities through regulation of p53-DNA binding activity.

Authors:  Kelly Lynn Harms; Xinbin Chen
Journal:  Cancer Res       Date:  2007-04-01       Impact factor: 12.701

9.  Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene.

Authors:  L K Su; K W Kinzler; B Vogelstein; A C Preisinger; A R Moser; C Luongo; K A Gould; W F Dove
Journal:  Science       Date:  1992-05-01       Impact factor: 47.728

10.  Human cyclin-dependent kinase 2 is activated during the S and G2 phases of the cell cycle and associates with cyclin A.

Authors:  J Rosenblatt; Y Gu; D O Morgan
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-01       Impact factor: 11.205

View more
  5 in total

1.  Regulation of VDR Expression in Apc-Mutant Mice, Human Colon Cancers and Adenomas.

Authors:  Charles Giardina; Masako Nakanishi; Awaad Khan; Anton Kuratnik; Wanli Xu; Bruce Brenner; Daniel W Rosenberg
Journal:  Cancer Prev Res (Phila)       Date:  2015-04-14

Review 2.  Histone deacetylases and mechanisms of regulation of gene expression.

Authors:  Hong Ping Chen; Yu Tina Zhao; Ting C Zhao
Journal:  Crit Rev Oncog       Date:  2015

3.  A flavonoid-rich extract from bergamot juice prevents carcinogenesis in a genetic model of colorectal cancer, the Pirc rat (F344/NTac-Apcam1137).

Authors:  Michele Navarra; Angelo Pietro Femia; Andrea Romagnoli; Katia Tortora; Cristina Luceri; Santa Cirmi; Nadia Ferlazzo; Giovanna Caderni
Journal:  Eur J Nutr       Date:  2019-03-27       Impact factor: 5.614

4.  Histone deacetylase 2 is involved in µ‑opioid receptor suppression in the spinal dorsal horn in a rat model of chronic pancreatitis pain.

Authors:  Yong-Hui Liao; Jian Wang; Yan-Yan Wei; Ting Zhang; Yong Zhang; Zhong-Fu Zuo; Xiao-Yu Teng; Yun-Qing Li
Journal:  Mol Med Rep       Date:  2017-12-11       Impact factor: 2.952

Review 5.  Epigenetics of Cutaneous Sarcoma.

Authors:  Emi Mashima; Yu Sawada
Journal:  Int J Mol Sci       Date:  2021-12-31       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.